Loading company…
ID 434172977 · FY 2019–2023 · 5 years
1.2 კომპანიის ძირითად საქმიანობას წარმოადგენს: - საბითუმო და საცალო ვაჭრობა ფარმაცევტული საქონლით.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 57.7% | 55.5% | 55.3% | 55.7% | 62.3% |
| EBITDA Margin | 33.5% | 24.9% | 30.9% | 36.6% | 25.4% |
| EBITDAR | 1,301 | 1,294 | 2,586 | 4,799 | 2,910 |
| EBITDAR Margin | 34.9% | 28.0% | 33.6% | 38.3% | 26.6% |
| EBIT Margin | 33.5% | 24.8% | 30.8% | 36.5% | 25.1% |
| Net Profit Margin | 32.0% | 17.5% | 36.5% | 37.7% | 23.4% |
| Operating Expense % of Sales | 24.3% | 30.6% | 24.4% | 19.1% | 36.9% |
| Returns | |||||
| Return on Assets (ROA) | 52.8% | 21.7% | 52.4% | 49.0% | 22.6% |
| Return on Equity (ROE) | 102.6% | 53.7% | 77.8% | 64.6% | 29.1% |
| ROIC [EBIT / Invested Capital] | 118.1% | 69.5% | 59.3% | 53.6% | 27.6% |
| Leverage & liquidity | |||||
| Debt-to-Assets | 0.0% | 10.8% | 9.8% | 13.9% | 10.5% |
| Debt-to-Equity | 0.00x | 0.27x | 0.15x | 0.18x | 0.13x |
| Debt-to-EBITDA | 0.00x | 0.35x | 0.22x | 0.29x | 0.43x |
| Equity-to-Assets | 51.5% | 40.5% | 67.4% | 75.8% | 77.6% |
| Net Debt | -105 | 144 | 383 | 1,231 | 1,161 |
| Cash & Equivalents | 105 | 258 | 142 | 107 | 25 |
| Total Debt | N/A | 402 | 526 | 1,338 | 1,186 |
| Efficiency & working capital | |||||
| Inventory Turnover | 1.74x | 1.17x | 1.93x | N/A | N/A |
| Days Inventory Outstanding (DIO) | 210.0 | 311.1 | 189.4 | N/A | N/A |
| Receivables Turnover | 3.59x | 3.28x | 2.67x | 2.18x | 1.91x |
| Days Sales Outstanding (DSO) | 101.7 | 111.2 | 136.6 | 167.8 | 190.7 |
| Payables Turnover | 1.51x | 1.18x | 3.20x | 6.30x | 3.06x |
| Days Payable Outstanding (DPO) | 241.4 | 309.4 | 114.2 | 57.9 | 119.2 |
| Cash Conversion Cycle | 70.3 days | 113.0 days | 211.8 days | 109.9 days | 71.5 days |
| Asset Turnover | 1.65x | 1.25x | 1.44x | 1.30x | 0.97x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 118 | 169 | -301 | 1,104 | 1,122 |
| Free Cash Flow (OCF − Capex proxy) | 118 | 169 | -301 | 136 | 1,122 |
| Cash Conversion (OCF / EBITDA) | 9.4% | 14.7% | -12.7% | 24.1% | 40.4% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).